Last checked at 
MANILA, Jan 10 (Reuters) - The Philippine government has
signed a deal to secure the supply of 30 million doses of the
COVID-19 vaccine Covovax from Serum Institute of India (SII),
the latter's local partner said on Sunday.
The agreement was signed on Saturday by Carlito Galvez, a
former military general in charge of the Philippines' strategy
to fight the coronavirus, according to a statement issued by
SII's local partner, Faberco Life Sciences Inc.
The Department of Health, which helped distribute the
Faberco statement to local media, has yet to issue its own
statement. Galvez could not be immediately reached for comment.
Health Secretary Francisco Duque in a tweet said: "We're in
the final stages of closing agreements with various
manufacturers to vaccinate at least 60-70% of the (population)".
He gave no further details.
SII partnered with U.S.-based Novavax Inc for the
development and commercialization of Covovax, which is in
third-stage trials and expected to be approved for use by
international regulators, Faberco said.
The vaccine will be available locally by the third quarter
of 2021 and will be used to inoculate 15 million vulnerable and
poor Filipinos, it said.
Galvez has said the Philippines was negotiating with seven
vaccine manufacturers to procure at least 148 million COVID-19
shots as it seeks to inoculate close to two-thirds of its
population this year.
Manila is hoping to close similar deals with Moderna
, AstraZeneca, Pfizer, Johnson & Johnson
, Sinovac Biotech and the Gamaleya Institute this
month.
There are now three applicants for emergency use
authorisation of their vaccines in the Philippines - Pfizer,
AstraZeneca, and Russia's Gamaleya.
With total confirmed COVID-19 infections of 487,690 and
deaths reaching 9,405, the Philippines has the second-highest
number of cases and fatalities in Southeast Asia, after
Indonesia.
(Reporting by Enrico Dela Cruz;
Editing by Bernadette Baum
)
